• Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI & Wensing AM (2010) Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. The Lancet Infectious Diseases 10, 155166.
  • Calmy A, Ford N, Hirschel B et al. (2007) HIV viral load monitoring in resource-limited regions: optional or necessary?. Clinical Infectious Diseases 44, 128134.
  • El-Khatib Z, Delong AK, Katzenstein D et al. (2011) Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa. Journal of AIDS & Clinical Research, 2, e1000117.
  • Fox Z, Phillips A, Cohen C et al. (2008) Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 22, 22792289.
  • Gallant JE, Rodriguez AE, Weinberg WG et al. (2005) Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. Journal of Infectious Diseases 192, 19211930.
  • Guidelines Development Group (2013). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. (eds A Harries & G Hirnschall) World Health Organization, Geneva, Switzerland, pp. 1269.
  • Gulick RM, Mellors JW, Havlir D et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 337, 734739.
  • Hoffmann CJ, Charalambous S, Sim J et al. (2009) Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clinical Infectious Diseases 49, 19281935.
  • Johnston V, Fielding K, Charalambous S et al. (2012) Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome. PLoS ONE 7, e36997.
  • Marconi VC, Sunpath H, Lu Z et al. (2008) Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clinical Infectious Diseases 46, 15891597.
  • McMahon JH, Manoharan A, Wanke CA et al. (2013) Pharmacy and self-report adherence measures to predict virological outcomes for patients on free antiretroviral therapy in Tamil Nadu, India. AIDS and Behavior 17, 22532259.
  • Orrell C, Harling G, Lawn SD et al. (2007) Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antiviral Therapy 12, 8388.
  • Peterson K, Menten J, Peterson I et al. (2013) Use of self-reported adherence and keeping clinic appointments as predictors of viremia in routine hiv care in the Gambia. Journal of the International Association of Providers of AIDS Care. [Epub ahead of print].
  • Pirkle CM, Boileau C, Nguyen VK et al. (2009) Impact of a modified directly administered antiretroviral treatment intervention on virological outcome in HIV-infected patients treated in Burkina Faso and Mali. HIV Medicine 10, 152156.
  • Rey D, Krebs M, Partisani M et al. (2006) Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes 43, 530534.
  • Thirumurthy H, Siripong N, Vreeman RC et al. (2012) Differences between self-reported and electronically monitored adherence among patients receiving antiretroviral therapy in a resource-limited setting. AIDS 26, 23992403.
  • Wagner GJ & Rabkin JG (2000) Measuring medication adherence: are missed doses reported more accurately then perfect adherence? AIDS Care 12, 405408.
  • Walmsley S, Bernstein B, King M et al. (2002) Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. New England Journal of Medicine 346, 20392046.
  • Wilson D, Keiluhu AK, Kogrum S et al. (2009) HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene 103, 601606.